ADCS


Also found in: Acronyms.

ADCS

Alzheimer’s Disease Cooperative Study. An initiative for Alzheimer's disease (AD) clinical studies by the US Federal government, addressing treatments for both cognitive and behavioral symptoms through a consortium of medical research centres and clinics located at 83 sites in the US and Canada. The ADCS is coordinated by the University of California, San Diego, and supported by the National Institute on Aging. The ADCS hopes to develop improved diagnostic tools and test various drugs to slow down the progression of autosomal dominant or prevent AD altogether.
References in periodicals archive ?
Analysis by Beacon Targeted Therapies shows that clinical trials for ADCs are already underway to test their effectiveness in treating a number of non-cancer indications.
M2 PHARMA-May 30, 2019-ADC Therapeutics Expands to Third Programme Using Synaffix's ADC Platform Under Existing Agreement
Investment from Venture Capital Trusts has allowed ADC Bio to invest in manufacturing and R&D to support its growth at Deeside.
Were excited to collaborate with Adagene to work toward the next generation of masked ADCs, said Chris Martin, Chief Executive Officer at ADC Therapeutics.
Following a high water mark of 8.6% in fiscal 2011, the median actuarially determined contribution (ADC) rose only 3.5% last year.
ADC Sialkot Tauqir Haider Kazmi was posted as ADC Lahore, Wasif Bashir Khokhar ADC General Kasur was posted as ADC Sheikhupura, Zamir Hussain ADC Sheikhupura was posted as OSD, Deputy Secretary Shafiq Ahmed was posted as ADC General Kasur, Ahmd Javed ADC General Nankana Sahib was posted as ADC General Chakwal, Mohammad Abbas ADC General Sialkot was posted as ADC General Nankana Sahib.
The b-value set used during diffusion weighted imaging has an impact on the fitting performance of the mono-exponential model and on the diagnostic performance of ADC consequently (16).
Day 1: Compare new generation HER-2 ADCs with Kadcyla[TM], examine technological advancements on PK-PD, highly potent ingredients, adc payloads and explore drug designs for ADCs; whilst Day 2 takes a look at fragmented drug conjugates and therapeutic windows, warheads and site selectivity, immune-oncological combination therapies, and design principles for maximising drug delivery.
Katsumi Fujimoto, PhD, senior executive officer, head of Supply Chain Division, Daiichi Sankyo, said, 'This strategic investment will bolster our leadership and expertise in ADC manufacturing, as we apply our proprietary ADC technology to more than two dozen biologics in preclinical or early stage development.
- Advancements in Linker Technology used for developing ADCs
Diffusion-weighted magnetic resonance imaging (DW-MRI), an imaging method exploiting in vivo Brownian motion of water molecules, has been increasingly performed on the abdomen, particularly in liver and kidney, over the past decade, [sup][1],[2] The apparent diffusion coefficient (ADC) is a quantitative parameter calculated from DW-MR images and is of potential clinical utility across a range of applications.
Oxford BioTherapeutics is developing a range of antibody-drug conjugates (ADCs) for the treatment of cancer.